Previous close | 49.27 |
Open | 49.39 |
Bid | 48.96 x 800 |
Ask | 48.97 x 1400 |
Day's range | 48.76 - 49.51 |
52-week range | 40.94 - 61.71 |
Volume | |
Avg. volume | 20,505,737 |
Market cap | 274.556B |
Beta (5Y monthly) | 0.62 |
PE ratio (TTM) | 9.52 |
EPS (TTM) | 5.14 |
Earnings date | 31 Oct 2022 - 04 Nov 2022 |
Forward dividend & yield | 1.60 (3.22%) |
Ex-dividend date | 28 Jul 2022 |
1y target est | 58.25 |
Based on results from a late-stage study, Sanofi (SNY) will discontinue the development of its breast cancer candidate, amcenestrant.
Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.
Yahoo Finance reporter Anjalee Khemlani details how the U.K. has approved a vaccine that targets both the original and omicron variants of the coronavirus.